Send to

Choose Destination
Oncoimmunology. 2018 Sep 6;7(12):e1511506. doi: 10.1080/2162402X.2018.1511506. eCollection 2018.

Trial watch: Peptide-based vaccines in anticancer therapy.

Bezu L1,2,3,4,5,6, Kepp O2,3,4,5,6, Cerrato G2,3,4,5,6, Pol J2,3,4,5,6, Fucikova J7,8, Spisek R7,8, Zitvogel L1,9,10, Kroemer G2,3,4,5,6,11,12, Galluzzi L5,13,14.

Author information

Faculty of Medicine, University of Paris Sud/Paris XI, Le Kremlin-Bicêtre, France.
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
Equipe 11 labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers,Paris, France.
U1138, INSERM, Paris, France.
Université Paris Descartes/Paris V, Paris, France.
Université Pierre et Marie Curie/Paris VI, Paris, France.
Sotio, Prague, Czech Republic.
Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic.
Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.
INSERM, U1015, Gustave Roussy Cancer Campus, Villejuif, France.
Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Sandra and Edward Meyer Cancer Center, New York, NY, USA.


Peptide-based anticancer vaccination aims at stimulating an immune response against one or multiple tumor-associated antigens (TAAs) following immunization with purified, recombinant or synthetically engineered epitopes. Despite high expectations, the peptide-based vaccines that have been explored in the clinic so far had limited therapeutic activity, largely due to cancer cell-intrinsic alterations that minimize antigenicity and/or changes in the tumor microenvironment that foster immunosuppression. Several strategies have been developed to overcome such limitations, including the use of immunostimulatory adjuvants, the co-treatment with cytotoxic anticancer therapies that enable the coordinated release of damage-associated molecular patterns, and the concomitant blockade of immune checkpoints. Personalized peptide-based vaccines are also being explored for therapeutic activity in the clinic. Here, we review recent preclinical and clinical progress in the use of peptide-based vaccines as anticancer therapeutics.Abbreviations: CMP: carbohydrate-mimetic peptide; CMV: cytomegalovirus; DC: dendritic cell; FDA: Food and Drug Administration; HPV: human papillomavirus; MDS: myelodysplastic syndrome; MHP: melanoma helper vaccine; NSCLC: non-small cell lung carcinoma; ODD: orphan drug designation; PPV: personalized peptide vaccination; SLP: synthetic long peptide; TAA: tumor-associated antigen; TNA: tumor neoantigen.


CAR T cells; MAGEA3; NY-ESO-1; immune checkpoint blockers; mutational load; synthetic long peptides; tumor neoantigens

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center